Results 31 to 40 of about 171,936 (295)

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Vaccines, 2023
We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received ...
Joel N. Maslow, Ijoo Kwon, Sagar B. Kudchodkar, Deborah Kane, Amha Tadesse, Hyojin Lee, Young K. Park, Kar Muthumani, Christine C. Roberts   +8 more
doaj   +1 more source

Antirabies DNA Immunization

Проблемы особо опасных инфекций, 2010
Cited are literary data related to the development of DNA vaccines against rabies virus. Research results regarding gene vaccination of different models of laboratory animals and different ways of vaccine introduction are presented.
I. V. Tuchkov, A. K. Nikiforov
doaj   +1 more source

Efficacy of DNA Vaccines in Protecting Rainbow Trout against VHS and IHN under Intensive Farming Conditions

, 2022
Despite the negative impact of viral hemorrhagic septicemia (VHS) and infectious hematopoietic necrosis (IHN) on European rainbow trout farming, no vaccines are commercially available in Europe.
Alessandra Buratin, Rasmussen, Jesper S., Francesco Pascoli, Luana Cortinovis, Pretto, Tobia, Toffan, Anna, Biasini, Lorena, Marco Vanelli, Abbadi, Miriam, Cortinovis, Luana, Paola Berto, Lorena Biasini, Simona Perulli, Manfrin, Amedeo, Vendramin, Niccolò, Pascoli, Francesco, Vanelli, Marco, Anna Toffan, Perulli, Simona, Amedeo Manfrin, Dagoberto Sepúlveda, Buratin, Alessandra, Andrea Marsella, Miriam Abbadi, Niccolò Vendramin, Berto, Paola, Tobia Pretto, Jesper S. Rasmussen, Sepúlveda, Dagoberto, Niels Lorenzen, Marsella, Andrea, Lorenzen, Niels   +31 more
core   +1 more source

Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. [PDF]

PLoS ONE, 2012
Although the use of recombinant hepatitis B virus surface (HBsAg) protein vaccine has successfully reduced global hepatitis B infection, there are still a number of vaccine recipients who do not develop detectable antibody responses.
Guohong Ge, Shixia Wang, Yaping Han, Chunhua Zhang, Shan Lu, Zuhu Huang   +5 more
doaj   +1 more source

An investigation of novel DNA based vaccines for protection against Brucellosis [PDF]

This thesis describes design, construction and evaluation in a BALB/c mouse model, for five novel Brucella specific DNA vaccines. Brucellosis is worldwide zoonosis of economic significance that poses a significant threat to both animal and human health ...
Commander, Nicola Jane
core   +1 more source

Vaccines against toxoplasma gondii : challenges and opportunities [PDF]

, 2009
Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects.
Craig W Roberts, Jongert, Erik, Förster-Wald, Elisabeth, Eskild Petersen, Erik Jongert, Gargano, Nicola, Roberts, Craig W., Roberts, Craig W, Petersen, Eskild, Nicola Gargano, Elisabeth Förster-Waldl   +10 more
core   +1 more source

Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study

Frontiers in Immunology, 2022
Current vaccination strategies against influenza focus on generating an antibody response against the viral haemagglutination surface protein, however there is increasing interest in neuraminidase (NA) as a target for vaccine development. A critical tool
Marie-Clotilde Bernard, Joanna Waldock, Sylvie Commandeur, Lea Strauß, Claudia Maria Trombetta, Serena Marchi, Fan Zhou, Serge van de Witte, Peter van Amsterdam, Sammy Ho, Katja Hoschler, Vladimir Lugovtsev, Jerry P. Weir, Emanuele Montomoli, Rebecca J. Cox, Othmar G. Engelhardt, Damien Friel, Ralf Wagner, Thierry Ollinger, Sophie Germain, Hanna Sediri-Schön   +20 more
doaj   +1 more source

Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines

Vaccines, 2019
DNA vaccines present one of the most cost-effective platforms to develop global vaccines, which have been tested for nearly three decades in preclinical and clinical settings with some success in the clinic.
Ashish C. Shrestha, Danushka K. Wijesundara, Makutiro G. Masavuli, Zelalem A. Mekonnen, Eric J. Gowans, Branka Grubor-Bauk   +5 more
doaj   +1 more source

Mixed allele malaria vaccines: Host protection and within-host selection [PDF]

, 2008
Malaria parasites are frequently polymorphic at the antigenic tat-gets of many candidate vaccines, presumably as a consequence of selection pressure from protective immune responses.
Anders, Robin F., Chan, Brian H.K., Barclay, Victoria C., Chan, Brian H K; id_orcid, Chan, Brian H. K., Read, Andrew F.   +5 more
core   +1 more source

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source